These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 35585696)

  • 1. A Pharmacokinetics-Time to Alleviation of Symptoms Model to Support Extrapolation of Baloxavir Marboxil Clinical Efficacy in Different Ethnic Groups with Influenza A or B.
    Retout S; De Buck S; Jolivet S; Duval V; Cosson V
    Clin Pharmacol Ther; 2022 Aug; 112(2):372-381. PubMed ID: 35585696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics, safety, and simulated efficacy of an influenza treatment, baloxavir marboxil, in Chinese individuals.
    Liu Y; Retout S; Duval V; Jia J; Zou Y; Wang Y; Cosson V; Jolivet S; De Buck S
    Clin Transl Sci; 2022 May; 15(5):1196-1203. PubMed ID: 35176206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of baloxavir marboxil versus neuraminidase inhibitors in the treatment of influenza virus infection in high-risk and uncomplicated patients - a Bayesian network meta-analysis.
    Taieb V; Ikeoka H; Wojciechowski P; Jablonska K; Aballea S; Hill M; Hirotsu N
    Curr Med Res Opin; 2021 Feb; 37(2):225-244. PubMed ID: 33079575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Baloxavir Marboxil 2% Granules in Japanese Children With Influenza: An Open-label Phase 3 Study.
    Yokoyama T; Sakaguchi H; Ishibashi T; Shishido T; Piedra PA; Sato C; Tsuchiya K; Uehara T
    Pediatr Infect Dis J; 2020 Aug; 39(8):706-712. PubMed ID: 32433222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Baloxavir Marboxil Single-dose Treatment in Influenza-infected Children: A Randomized, Double-blind, Active Controlled Phase 3 Safety and Efficacy Trial (miniSTONE-2).
    Baker J; Block SL; Matharu B; Burleigh Macutkiewicz L; Wildum S; Dimonaco S; Collinson N; Clinch B; Piedra PA
    Pediatr Infect Dis J; 2020 Aug; 39(8):700-705. PubMed ID: 32516282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The antiviral effects of baloxavir marboxil against influenza A virus infection in ferrets.
    Kitano M; Matsuzaki T; Oka R; Baba K; Noda T; Yoshida Y; Sato K; Kiyota K; Mizutare T; Yoshida R; Sato A; Kamimori H; Shishido T; Naito A
    Influenza Other Respir Viruses; 2020 Nov; 14(6):710-719. PubMed ID: 32533654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Baloxavir marboxil in Japanese patients with seasonal influenza: Dose response and virus type/subtype outcomes from a randomized phase 2 study.
    Watanabe A; Ishida T; Hirotsu N; Kawaguchi K; Ishibashi T; Shishido T; Sato C; Portsmouth S; Tsuchiya K; Uehara T
    Antiviral Res; 2019 Mar; 163():75-81. PubMed ID: 30684563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Baloxavir Treatment in Adolescents With Acute Influenza: Subgroup Analysis From the CAPSTONE-1 Trial.
    Portsmouth S; Hayden FG; Kawaguchi K; Ishibashi T; Kinoshita M; Shishido T; Tsuchiya K; Uehara T
    J Pediatric Infect Dis Soc; 2021 Apr; 10(4):477-484. PubMed ID: 33340316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic and pharmacodynamic analysis of baloxavir marboxil, a novel cap-dependent endonuclease inhibitor, in a murine model of influenza virus infection.
    Ando Y; Noshi T; Sato K; Ishibashi T; Yoshida Y; Hasegawa T; Onishi M; Kitano M; Oka R; Kawai M; Yoshida R; Sato A; Shishido T; Naito A
    J Antimicrob Chemother; 2021 Jan; 76(1):189-198. PubMed ID: 33035324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Antiviral Agents for Seasonal Influenza Outcomes in Healthy Adults and Children: A Systematic Review and Network Meta-analysis.
    Liu JW; Lin SH; Wang LC; Chiu HY; Lee JA
    JAMA Netw Open; 2021 Aug; 4(8):e2119151. PubMed ID: 34387680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical efficacy and safety of baloxavir marboxil in the treatment of influenza: A systematic review and meta-analysis of randomized controlled trials.
    Kuo YC; Lai CC; Wang YH; Chen CH; Wang CY
    J Microbiol Immunol Infect; 2021 Oct; 54(5):865-875. PubMed ID: 34020891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Comparison of the Frequency of Prescription and Pharmacy Revisits between Baloxavir Marboxil and Neuraminidase Inhibitors in Influenza-Infected Pediatric Patients during the 2019-2020 Influenza Season.
    Norikoshi Y; Ikeda T; Sasahara K; Hamada M; Torigoe E; Nagae M; Tashiro T; Horio F; Saruwatari J; Uchida Y; Anraku M
    Biol Pharm Bull; 2020; 43(12):1960-1965. PubMed ID: 33268716
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Duration of fever and symptoms in children after treatment with baloxavir marboxil and oseltamivir during the 2018-2019 season and detection of variant influenza a viruses with polymerase acidic subunit substitutions.
    Saito R; Osada H; Wagatsuma K; Chon I; Sato I; Kawashima T; Saito T; Kodo N; Ono Y; Shimada Y; Phyu W; Shobugawa Y
    Antiviral Res; 2020 Nov; 183():104951. PubMed ID: 32987032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population Pharmacokinetics and Exposure-Response Relationships of Baloxavir Marboxil in Influenza Patients at High Risk of Complications.
    Koshimichi H; Retout S; Cosson V; Duval V; De Buck S; Tsuda Y; Ishibashi T; Wajima T
    Antimicrob Agents Chemother; 2020 Jun; 64(7):. PubMed ID: 32312784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Open-label study of the safety, pharmacokinetics, and effectiveness of a 2 mg/kg dose of baloxavir marboxil 2% granules in children <20 kg with influenza.
    Sonoyama T; Sakaguchi H; Koshimichi H; Noshi T; Tsuchiya K; Uehara T
    J Infect Chemother; 2021 Aug; 27(8):1223-1229. PubMed ID: 34045119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and safety of a novel influenza treatment (baloxavir marboxil) in Korean subjects compared with Japanese subjects.
    Kim Y; Lee S; Kim Y; Jang IJ; Lee S
    Clin Transl Sci; 2022 Feb; 15(2):422-432. PubMed ID: 34664769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and effectiveness of baloxavir marboxil for the treatment of influenza in Japanese clinical practice: A postmarketing surveillance of more than 3000 patients.
    Nakazawa M; Hara K; Komeda T; Ogura E
    J Infect Chemother; 2020 Jul; 26(7):729-735. PubMed ID: 32409018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Baloxavir Marboxil Treatment of Nude Mice Infected With Influenza A Virus.
    Kiso M; Yamayoshi S; Murakami J; Kawaoka Y
    J Infect Dis; 2020 Apr; 221(10):1699-1702. PubMed ID: 31837268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Baloxavir Marboxil for Prophylaxis against Influenza in Household Contacts.
    Ikematsu H; Hayden FG; Kawaguchi K; Kinoshita M; de Jong MD; Lee N; Takashima S; Noshi T; Tsuchiya K; Uehara T
    N Engl J Med; 2020 Jul; 383(4):309-320. PubMed ID: 32640124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of Variants With Reduced Baloxavir Marboxil Susceptibility After Treatment of Children With Influenza A During the 2018-2019 Influenza Season.
    Sato M; Takashita E; Katayose M; Nemoto K; Sakai N; Hashimoto K; Hosoya M
    J Infect Dis; 2020 Jun; 222(1):121-125. PubMed ID: 32034420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.